CMG Pharmaceutical Co. Ltd Asset Resilience Ratio
CMG Pharmaceutical Co. Ltd asset resilience ratio. CMG Pharmaceutical Co. Ltd (058820) has an Asset Resilience Ratio of 6.66% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See CMG Pharmaceutical Co. Ltd (058820) liquidity interval to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of CMG Pharmaceutical Co. Ltd (2011–2025)
Asset resilience ratio of CMG Pharmaceutical Co. Ltd from 2011 to 2025. This chart shows how CMG Pharmaceutical Co. Ltd's Asset Resilience Ratio has changed over time. Read debt load of CMG Pharmaceutical Co. Ltd for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down CMG Pharmaceutical Co. Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see CMG Pharmaceutical Co. Ltd (058820) total assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 0% |
| Short-term Investments | ₩20.38 Billion | 6.66% |
| Total Liquid Assets | ₩20.38 Billion | 6.66% |
Asset Resilience Insights
- Limited Liquidity: CMG Pharmaceutical Co. Ltd maintains only 6.66% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
CMG Pharmaceutical Co. Ltd Industry Peers by Asset Resilience Ratio
Compare CMG Pharmaceutical Co. Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Jiangsu Nhwa Pharmaceutical Co Ltd
SHE:002262 |
Drug Manufacturers - Specialty & Generic | 26.45% |
|
Tibet Rhodiola Pharmaceutical Holding Co
SHG:600211 |
Drug Manufacturers - Specialty & Generic | 11.84% |
|
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091 |
Drug Manufacturers - Specialty & Generic | 26.36% |
|
Renhe Pharmacy Co Ltd
SHE:000650 |
Drug Manufacturers - Specialty & Generic | 37.54% |
|
Bide Pharmatech Co. Ltd. A
SHG:688073 |
Drug Manufacturers - Specialty & Generic | 9.46% |
|
Jianmin Pharmaceutical Group Co Ltd
SHG:600976 |
Drug Manufacturers - Specialty & Generic | 20.61% |
|
Qianjiang Yongan Pharmaceutical Co Ltd
SHE:002365 |
Drug Manufacturers - Specialty & Generic | 30.38% |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078 |
Drug Manufacturers - Specialty & Generic | 0.42% |
CMG Pharmaceutical Co. Ltd Asset Resilience Ratio by Year (2011–2025)
CMG Pharmaceutical Co. Ltd asset resilience ratio by year from 2011 to 2025. The table below shows the annual Asset Resilience Ratio data for CMG Pharmaceutical Co. Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 6.66% | ₩20.38 Billion ≈ $13.81 Million |
₩305.96 Billion ≈ $207.35 Million |
-17.79pp |
| 2024-12-31 | 24.46% | ₩74.21 Billion ≈ $50.29 Million |
₩303.44 Billion ≈ $205.63 Million |
-3.46pp |
| 2023-12-31 | 27.92% | ₩67.58 Billion ≈ $45.80 Million |
₩242.10 Billion ≈ $164.07 Million |
-6.48pp |
| 2022-12-31 | 34.40% | ₩73.36 Billion ≈ $49.71 Million |
₩213.26 Billion ≈ $144.52 Million |
-10.96pp |
| 2021-12-31 | 45.36% | ₩90.34 Billion ≈ $61.22 Million |
₩199.17 Billion ≈ $134.98 Million |
-10.84pp |
| 2020-12-31 | 56.19% | ₩109.78 Billion ≈ $74.39 Million |
₩195.36 Billion ≈ $132.39 Million |
-6.01pp |
| 2019-12-31 | 62.20% | ₩119.57 Billion ≈ $81.03 Million |
₩192.24 Billion ≈ $130.28 Million |
+14.58pp |
| 2018-12-31 | 47.62% | ₩54.46 Billion ≈ $36.91 Million |
₩114.38 Billion ≈ $77.51 Million |
-4.22pp |
| 2017-12-31 | 51.84% | ₩56.80 Billion ≈ $38.49 Million |
₩109.57 Billion ≈ $74.25 Million |
-1.47pp |
| 2016-12-31 | 53.31% | ₩59.16 Billion ≈ $40.09 Million |
₩110.98 Billion ≈ $75.21 Million |
+44.46pp |
| 2015-12-31 | 8.84% | ₩5.00 Billion ≈ $3.39 Million |
₩56.53 Billion ≈ $38.31 Million |
+8.37pp |
| 2014-12-31 | 0.48% | ₩278.19 Million ≈ $188.53K |
₩58.07 Billion ≈ $39.35 Million |
-0.02pp |
| 2013-12-31 | 0.50% | ₩278.19 Million ≈ $188.53K |
₩55.91 Billion ≈ $37.89 Million |
-52.64pp |
| 2012-12-31 | 53.14% | ₩30.35 Billion ≈ $20.57 Million |
₩57.11 Billion ≈ $38.70 Million |
+49.22pp |
| 2011-12-31 | 3.92% | ₩1.07 Billion ≈ $726.07K |
₩27.31 Billion ≈ $18.50 Million |
-- |
About CMG Pharmaceutical Co. Ltd
CMG Pharmaceutical Co., Ltd., a pharmaceutical company, develops and sells oral thin film (OTF) pharmaceuticals in South Korea. It offers Tadalafil OTF products for erectile dysfunction; Entecavir OTF products to treat hepatitis type B; Aripiprazole OTF products for schizophrenia; and Montelukast OTF products to treat asthma and allergic rhinitis. CMG Pharmaceutical Co. Ltd. has a strategic colla… Read more